Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis.
Olga KryštůfkováHana HulejováHeřman F MannOndřej PechaIvana PůtováLouise EkholmIngrid E LundbergJiří VencovskýPublished in: Arthritis research & therapy (2018)
Our findings of associations between levels of BAFF and anti-Jo-1 antibodies in serum and myositis activity suggest a role of this cytokine in disease-specific autoantibody production as part of disease mechanisms, and support BAFF as a potential target for intervention in anti-Jo-1-positive myositis patients.
Keyphrases
- disease activity
- interstitial lung disease
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- randomized controlled trial
- systemic sclerosis
- ankylosing spondylitis
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- signaling pathway
- peritoneal dialysis
- prognostic factors
- climate change
- risk assessment